Rationale of techni- cal requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Pract Radiat Oncol. 2016; 6: e291-e298. https://doi.org/10.1016/j.prro.2016.05.004 PMID: 27345129
Introduction In 2014, the NRG Oncology Group initiated the first National Cancer Institute-sponsored, phase 1 clinical trial of stereotactic body radiation therapy (SBRT) for the treatment of multiple metastases in multiple organ sites (BR001; NCT02206334). The primary endpoint is to test the safet...
Purpose The NRG-BR001 trial is the first National Cancer Institute–sponsored trial to treat multiple (range 2-4) extracranial metastases with stereotactic body radiation therapy. Benchmark credentialing is required to ensure adherence to this complex protocol, in particular, for metastases in close ...
Radiation-Induced Toxicity in the Era of Stereotactic Body Radiation Therapy—Lessons From NRG-BR001doi:10.1001/jamaoncol.2021.0677toxic effectstereotactic body radiotherapyCharles R.ThomasJr,MDJAMA Oncology